Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2025-05-28 00:00:00 ET · period of report 2025-05-23 · accession 0000950170-25-078457 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-28 | 2025-05-23 | LAB | Egholm Michael | Pres, CEO, Dir | S - Sale | $0.94 | -5,473 | 2.74M | -0.2% | -$5,145 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-23 | S | D | 5,473 | $0.94 | 2,741,191 | D | — | — | (F1) The shares were sold to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025. (F2) Represents the weighted average sales price per share. The shares sold at prices ranging from $0.92 to $0.9748 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. |